Journal of Gastroenterology

, Volume 45, Issue 10, pp 999–1007 | Cite as

Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis

  • Ayako Kobori
  • Yuhki Yagi
  • Hirotsugu Imaeda
  • Hiromitsu Ban
  • Shigeki Bamba
  • Tomoyuki Tsujikawa
  • Yasuharu Saito
  • Yoshihide Fujiyama
  • Akira Andoh
Original Article—Alimentary Tract

Abstract

Background

Interleukin (IL)-33 is a cytokine belonging to the IL-1 family. IL-33 has been shown to elicit a Th2-like cytokine response in immune cells. In this study, we investigated IL-33 expression in the inflamed mucosa of patients with inflammatory bowel disease (IBD), and characterized the molecular mechanisms responsible for IL-33 expression in human colonic subepithelial myofibroblasts (SEMFs).

Methods

IL-33 mRNA expression was determined by real-time polymerase chain reaction (PCR). IL-33 expression in the IBD mucosa was evaluated by immunohistochemical methods.

Results

IL-33 mRNA expression was significantly elevated in active lesions from patients with ulcerative colitis (UC), but was not detected in inactive lesions from UC patients or in lesions from patients with either active or inactive Crohn’s disease. Colonic SEMFs were identified as a major source of IL-33 in the mucosa. IL-1β and tumor necrosis factor-α (TNF-α) significantly enhanced IL-33 mRNA and protein expression in isolated colonic SEMFs. IL-1β and TNF-α did not affect IL-33 expression in intestinal epithelial cell lines (HT-29 and Caco-2 cells). This IL-1β- and TNF-α-induced IL-33 mRNA expression was mediated by p42/44 mitogen activated protein kinase (MAPK) pathway-dependent activation of nuclear factor (NF)-κB and activator protein (AP)-1.

Conclusions

IL-33, derived from colonic SEMFs, may play an important role in the pathophysiology of UC.

Keywords

IBD Cytokine Biomarker 

References

  1. 1.
    Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538–49.CrossRefPubMedGoogle Scholar
  3. 3.
    Nishida A, Andoh A, Imaeda H, Sugihara T, Inatomi O, Shiomi H, et al. Expression of interleukin-1-like cytokine interleukin-33 and its receptor complex (ST2L and IL-1RAcP) in human pancreatic myofibroblasts. Gut. 2010;59(4):531–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Marvie P, Lisbonne M, L’Helgoualc’h A, Rauch M, Turlin B, Preisser L, et al. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med. 2009 (Epub ahead of print).Google Scholar
  5. 5.
    Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 2008;43:1–17.CrossRefPubMedGoogle Scholar
  6. 6.
    Mayer L. Evolving paradigms in the pathogenesis of IBD. J Gastroenterol. 2010;45:9–16.CrossRefPubMedGoogle Scholar
  7. 7.
    Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol. 2007;42:16–25.CrossRefPubMedGoogle Scholar
  8. 8.
    Seidelin JB, Bjerrum JT, Coskun M, Widjaya B, Vainer B, et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett. 2010;28:80–5.CrossRefGoogle Scholar
  9. 9.
    Beltran CJ, Nunez LE, Diaz-Jimenez D, Farfan N, Candia E, Heine C, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009 (Epub ahead of print).Google Scholar
  10. 10.
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn’s disease activity index (CDAI). Gastroenterology. 1979;77:843–6.PubMedGoogle Scholar
  12. 12.
    Mahida YR, Beltinger J, Makh S, Goke M, Gray T, Podolsky DK, et al. Adult human colonic subepithelial myofibroblasts express extracellular matrix proteins and cyclooxygenase-1 and -2. Am J Physiol. 1997;273:G1341–8.PubMedGoogle Scholar
  13. 13.
    Andoh A, Fujino S, Bamba S, Araki Y, Okuno T, Bamba T, et al. IL-17 selectively down-regulates TNF-alpha-induced RANTES gene expression in human colonic subepithelial myofibroblasts. J Immunol. 2002;169:1683–7.PubMedGoogle Scholar
  14. 14.
    Shimada M, Andoh A, Hata K, Tasaki K, Araki Y, Fujiyama Y, et al. IL-6 secretion by human pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol. 2002;168:861–8.PubMedGoogle Scholar
  15. 15.
    Obara H, Takayanagi A, Hirahashi J, Tanaka K, Wakabayashi G, Matsumoto K, et al. Overexpression of truncated IkappaBalpha induces TNF-alpha-dependent apoptosis in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20:2198–204.PubMedGoogle Scholar
  16. 16.
    Yasumoto H, Kim S, Zhan Y, Miyazaki H, Hoshiga M, Kaneda Y, et al. Dominant negative c-jun gene transfer inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in rats. Gene Ther. 2001;8:1682–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384:105–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y, et al. IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol. 2002;282:G1035–44.PubMedGoogle Scholar
  19. 19.
    Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 1995;270:27489–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 1998;273:18623–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995;364:229–33.CrossRefPubMedGoogle Scholar
  22. 22.
    Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007;19:2487–97.CrossRefPubMedGoogle Scholar
  23. 23.
    Ding SZ, Olekhnovich IN, Cover TL, Peek RM Jr, Smith MF Jr, Goldberg JB. Helicobacter pylori and mitogen-activated protein kinases mediate activator protein-1 (AP-1) subcomponent protein expression and DNA-binding activity in gastric epithelial cells. FEMS Immunol Med Microbiol. 2008;53:385–94.CrossRefPubMedGoogle Scholar
  24. 24.
    Mukhopadhyay S, Mukherjee S, Smith M, Das SK. Activation of MAPK/AP-1 signaling pathway in lung injury induced by 2-chloroethyl ethyl sulfide, a mustard gas analog. Toxicol Lett. 2008;181:112–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;183:5094–103.CrossRefPubMedGoogle Scholar
  26. 26.
    Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521–33.CrossRefPubMedGoogle Scholar
  27. 27.
    Holtta V, Klemetti P, Sipponen T, Westerholm-Ormio M, Kociubinski G, Salo H, et al. IL-23/IL-17 immunity as a hallmark of Crohn’s disease. Inflamm Bowel Dis. 2008;14:1175–84.CrossRefPubMedGoogle Scholar
  28. 28.
    Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol. 2009;123:1047–54.CrossRefPubMedGoogle Scholar
  29. 29.
    Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol. 2007;82:1481–90.CrossRefPubMedGoogle Scholar
  30. 30.
    Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–64.PubMedGoogle Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Ayako Kobori
    • 1
  • Yuhki Yagi
    • 1
  • Hirotsugu Imaeda
    • 1
  • Hiromitsu Ban
    • 1
  • Shigeki Bamba
    • 1
  • Tomoyuki Tsujikawa
    • 1
  • Yasuharu Saito
    • 1
  • Yoshihide Fujiyama
    • 1
  • Akira Andoh
    • 2
  1. 1.Department of MedicineShiga University of Medical ScienceOtsuJapan
  2. 2.Division of Mucosal Immunology, Graduate School of MedicineShiga University of Medical ScienceOtsuJapan

Personalised recommendations